SDG
Developer of bio-nanotechnology delivery systems focused on nanoscale bilayer phospholipid carriers (20–50 nm) for oral protein delivery, cell-receptor targeting, and consumer-product actives. Technologies have been evaluated in human clinical studies and the company supports cGMP manufacturing, stability testing, and technology licensing/partnerships.
Industries
Nr. of Employees
small (1-50)
SDG
10000 Cedar Avenue, Cleveland, Ohio 44106 Fax: 216-274-9529
Patents
Products
Hepatic-targeted vesicle formulations for oral protein delivery
Vesicle-based formulations designed to deliver protein therapeutics to the liver via oral administration for metabolic disease indications.
Bio-nano liposome carriers for therapeutic, diagnostic, and consumer actives
Nanoscale bilayer carriers compatible with proteins, small molecules, imaging agents, nutraceuticals, fragrances, sunscreens, and hair/skin actives.
Hepatic-targeted vesicle formulations for oral protein delivery
Vesicle-based formulations designed to deliver protein therapeutics to the liver via oral administration for metabolic disease indications.
Bio-nano liposome carriers for therapeutic, diagnostic, and consumer actives
Nanoscale bilayer carriers compatible with proteins, small molecules, imaging agents, nutraceuticals, fragrances, sunscreens, and hair/skin actives.
Services
Licensing of bio-nano delivery technologies and collaborative development agreements with industry partners and contract collaborators.
Commercial-scale manufacturing of nanoscale bilayer carrier systems under current Good Manufacturing Practices.
Licensing of bio-nano delivery technologies and collaborative development agreements with industry partners and contract collaborators.
Commercial-scale manufacturing of nanoscale bilayer carrier systems under current Good Manufacturing Practices.
Expertise Areas
- Oral protein delivery
- Nanoparticle/bilayer vesicle formulation
- Cell-receptor targeted drug delivery
- Preclinical and clinical study execution
Key Technologies
- Bilayer phospholipid vesicle carriers (20–50 nm)
- Cell-receptor targeting ligands
- Immune-masking agents (non-PEG)
- Oral protein formulation
News & Updates
Signing of a comprehensive joint development and licensing agreement to develop and commercialize combined nano-formulations and bio-active nanotechnologies.
Poster describing a food-dose timing clinical trial of an oral hepatic-targeted vesicle insulin formulation in Type 2 diabetes patients.
Review covering formulation development and preclinical evaluation of hepatic-directed vesicle insulin.
Journal article on portal serotonin infusion and its effects on glucose disposal (preclinical study).
Delivery systems tested in more than four hundred human subjects and reported as safe and efficacious in disease areas including diabetes and hepatitis.
Signing of a comprehensive joint development and licensing agreement to develop and commercialize combined nano-formulations and bio-active nanotechnologies.
Poster describing a food-dose timing clinical trial of an oral hepatic-targeted vesicle insulin formulation in Type 2 diabetes patients.
Review covering formulation development and preclinical evaluation of hepatic-directed vesicle insulin.
Journal article on portal serotonin infusion and its effects on glucose disposal (preclinical study).
Delivery systems tested in more than four hundred human subjects and reported as safe and efficacious in disease areas including diabetes and hepatitis.